Tumour suppressor genes are frequently affected by somatic alterations in cancer, and the impairment of their normal function provides a strong contribution to tumourigenesis. Short-hairpin (sh) RNA library screens have been employed as powerful genetic tools to uncover important new players in human cancer 1-5 . To identify potential novel tumour suppressor genes acting in the p53 pathway, we performed an shRNA screen using a cell-based model in which only a single additional genetic event disrupting the p53 pathway is required to obtain in vitro transformation. By using this approach, we report here on the identification of the Frizzled-ligand Norrin (Norrie disease protein) as a candidate tumour suppressor.
Introduction
The development of in vitro step-wise transformation assays using normal diploid human cells of different origins has provided important insights into the molecular mechanisms leading to cancer 6, 7 . These assays in combination with the availability of short-hairpin (sh)RNA libraries enable loss-of-function screenings in mammalian cells 8 .
To identify novel candidate tumour suppressor genes with a potential function in the p53 pathway, we performed a retroviral shRNA library screen in a human cell model prone for transformation ( Fig. 1a ). We used the human diploid lung fibroblast cell line, TIG3 as a model system for transformation. These cells are transformed when expressing the human telomerase catalytic subunit (hTERT), an shRNA targeting pRB, an shRNA targeting p53, H-RASV12 and the SV40 small t-antigen (ST). In the cell system used for the screen we omitted the shRNA targeting p53, and the transformation prone TIG3 cells therefore expressed TERT, shRNA pRB, ST and H-RASV12. These cells were infected with a retroviral shRNA library targeting approximately 8000 human genes 1 and selected for anchorage-independent growth (Fig. 1a ). The shRNA inserts from the recovered colonies were then amplified by PCR, and re-cloned for sequencing and validation.
Results
The quality of the screen was underscored by the fact that we identified an shRNA targeting p53 in our screen (data not shown). Among other shRNAs, we identified one targeting Norrin (shNorrin#1). Norrin is a cystein-knot protein whose mutation is associated with the Norrie disease, a syndrome characterized by congenital blindness, deafness and mental retardation [9] [10] [11] . To validate the screen and Norrin as a putative tumour suppressor gene, we re-infected the cells used in the original screen with shRNANorrin#1 and determined the number of anchorage-independent colonies.
The cells were also infected with an empty retrovirus as a negative control and a retrovirus expressing an shRNA to p53 as a positive control. As shown in Figure 1b , shNorrin#1 was indeed able to confer anchorage-independent growth to the transformation prone diploid fibroblasts. By RT-QPCR, we confirmed that the endogenous Norrin mRNA level was specifically reduced by shNorrin#1 in the same experiment ( Fig. 1c ).
Since loss of p53 bypasses proliferation arrest induced in diploid cells grown at
low cell density 1 we tested whether the inhibition of Norrin expression could confer a similar phenotype. Thus, we infected TIG3-TERT (TIG3-T) cells with two different vectors expressing shRNAs to Norrin and the appropriate controls, and indeed, the inhibition of Norrin expression allowed cells to grow more efficiently when seeded at low density ( Fig. 1d , e; Supplementary Figure 1a , b).
Next, we asked whether acute Norrin depletion could affect the p53 pathway.
We stably expressed two shRNAs targeting Norrin in TIG3-T cells and determined the expression levels of p53 by immunoblot. Downregulation of Norrin expression led to a substantial reduction in p53 protein levels ( Fig. 2a ), without affecting p53 mRNA levels ( Fig. 2b ).
Interestingly, Norrin was proposed to be a novel ligand for the Frizzled-LRP receptor complexes 12, 13 . Norrin is a secreted protein, which acts through the Frizzled 4 (FZD4) receptor to activate the WNT/-catenin pathway 12, 13 . Consistent with this, inhibition of Norrin expression led to the down regulation of the -catenin target gene AXIN2 ( Fig. 2c , Supplementary Fig. S2a, b ).
Increased -catenin activity was previously shown to increase p53 levels and the activation of a p53-mediated anti-proliferative response 14, 15 . Since Norrin increases the expression of -catenin target genes, the -catenin pathway may link Norrin to p53.
Consistent with this, inhibition of -catenin led to reduced p53 protein levels, while p53 mRNA levels were not affected ( Fig. 2d ).
In agreement with previous studies 12, 13 we also confirmed Norrin as an activator of the WNT/-catenin pathway. The treatment of TIG3-T cells with recombinant human Norrin (rhNorrin) led to increased expression of AXIN2 mRNA ( Supplementary   Fig. 2c ). Furthermore, treatment with rhNorrin of the U2OS human osteosarcoma cell line, led to -catenin stabilization ( Supplementary Fig. 2d ).
Next, to complement our results showing that inhibition of Norrin and -catenin expression reduces p53 protein levels, we asked whether exposure of TIG3-T cells to rhNorrin results in increased p53 protein levels. As shown in Figure 2e , the treatment of TIG3-T cells with rhNorrin indeed triggers p53 accumulation, without leading to a significant increase in p53 mRNA levels. Interestingly, the accumulation of p53 induced by rhNorrin is decreased in cells where -catenin is down regulated ( Fig. 2e ).
Taken together these results suggest that increased Norrin levels result in the accumulation of p53 through the activation of -catenin.
Moreover, treatment of TIG3-T cells with rhNorrin induces a p53-dependent inhibition of cell proliferation ( Supplementary Fig. 3 ), suggesting that Norrin, through the activation of -catenin, triggers a p53-mediated anti-proliferative response.
When cells are affected by oncogenic stimuli that lead to inappropriate proliferative signals, tumour suppressor genes are frequently activated 16, 17 . Thus, we asked whether Norrin expression is increased in response to oncogene activation. We found that Norrin is expressed at low levels in TIG3-T cells, while it is dramatically increased in the transformation-prone cells used in the screens (Fig. 3a ). Next, we investigated which of the oncogenic stimuli present in the transformation prone cells could lead to increased levels of Norrin. As shown in Figure 3b , H-RASV12 expression led to a significant increase in Norrin levels (Fig. 3b ).
RAS activates multiple signalling cascades including AKT, RALGDS, RAC, MAPK and ERK 18 . To further explore the mechanism by which RAS signalling induces Norrin expression, we investigated whether activation of RAF could induce Norrin mRNA as efficiently as oncogenic RAS. Therefore, we used TIG3-T cells expressing a BRAF-ER fusion protein, which is activated by the addition of 4-hydroxy tamoxifen (OHT). Indeed, the activation of RAF led to a strong increase of Norrin mRNA ( Fig. 3c ).
To further investigate the cascade involved in H-RASV12 -induced increase in
Norrin expression, we treated cells expressing H-RASV12 or BRAF-ER with inhibitors of PI3K (Wortmannin), MEK/ERK (U0126, PD98059) and p38/MAPK (SB203580) kinases. Norrin induction by H-RASV12 and BRAF was efficiently blocked by U0126 and PD98059 alone, whereas Wortmannin and SB203580 had partial inhibitory effects ( Fig. 3d ). When SB203580 was combined with U0126, Norrin induction by BRAF was at levels similar to U0126 treatment alone ( Fig. 3e ). Taken together, these data suggest that RASV12 induces the expression of Norrin through the RAF-MEK-ERK pathway ( Fig. 3f ).
Since our results demonstrated that Norrin acts as a tumour suppressor in a transformation assay, we analyzed the expression levels of Norrin in cell lines and primary tumours. Melanomas are frequently affected by oncogenic mutations in RAS and BRAF 19 . Thus, we analysed whether Norrin expression is decreased in primary and metastatic melanoma cell lines. Indeed, Norrin expression level is decreased in metastatic melanoma cells ( Fig. 4a , b, c); in addition, analyses of patient -matched primary and metastatic melanoma cell lines further confirmed that Norrin is strongly downregulated in metastasis ( Fig. 4 b, c). To obtain further information on Norrin expression in other cancer types, we searched the Oncomine database 19 . Norrin expression is significantly decreased in aggressive breast tumours as compared to the more benign stages ( Fig. 4 d, e ). In addition, Norrin expression inversely correlates with tumour grade in prostate and endometrial cancer ( Fig. 4f, g) , and is significantly down regulated in ovarian and prostate tumours when compared to normal ovarian and prostate tissues ( Supplementary Fig. 4 a, b ).
Discussion
The WNT/β-catenin signalling pathway is frequently activated in human cancers 20 . However, as already shown for other major oncogenic signalling pathways, most notably the RAS-RAF pathway, oncogene activation, in this case β-catenin, promotes accumulation of p53 thus leading to growth arrest 14, 15 .
Here we have shown that Norrin can act as a tumour suppressor gene. Indeed, depletion of Norrin expression by shRNA can substitute for the inactivation of p53 in cellular transformation assays.
Increase of Norrin levels induced by oncogene activation activate -catenin, most likely through an autocrine/paracrine pathway involving the binding of Norrin to the Frizzled receptors, FZD4/LRP5 and the TSPAN12 co-receptor 21, 22 . Subsequently Norrin stimulates a -catenin dependent accumulation of p53, which in turn triggers a p53-mediated anti-proliferative response (Fig. 4h ). Therefore, Norrin is part of a failsafe mechanism preventing tumour-induction elicited by oncogenic RAS-signalling through the RAF-ERK cascade.
Our findings suggest that Norrin, a non-conventional WNT ligand, could be a previously unappreciated secreted tumour suppressor. Indeed, Norrin expression is triggered by aberrant oncogenic stimuli, positively regulates p53 stability and is downregulated in multiple tumour types and during cancer progression.
Since Norrin acts as a WNT ligand, which is induced by the RAS-RAF pathway, we provide a novel link between the RAS and WNT/-catenin pathways. Further investigations are required to elucidate a potential role for Norrin in tumourigenesis.
METHODS

Plasmids
The following plasmids were used: pWZL-Neo Ecotropic receptor 23 , pBABE-Hygro hTERT 6 
Anchorage independent growth
Approximately 100,000 cells were plated in 0.45% low melting temperature agarose (Sea Plaque GTG agarose)/growth media onto 6-well dishes with a 0.9% agarose underlay. Colonies were counted from triplicate wells after three weeks, and the total number is shown.
Colony-formation assays
TIG3-T cells were infected with the indicated vectors, and plated after antibiotic selection at the indicated cell numbers in 6 cm or 10 cm dishes and stained with Crystal violet after 2 weeks.
Growth curves
TIG3 cells were infected with the indicated retroviral vectors, and after selection 30,000 cells were plated in 6 well plates (time = 0 days). Every 3 days, cells were counted and 30,000 cells were replated. Total cell amounts in all growth curves were displayed as cumulative over time, and calculated as in 25 .
shRNA sequences
The targeting sequences of the shRNAs present in the retroviral plasmids are listed in Supplementary methods.
Data mining
Information regarding data mining is given in supplementary methods.
Additional materials and methods
Additional materials and methods are described in the supplementary method section.
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